Crescent Biopharma (NASDAQ:CBIO) Stock Rating Upgraded by Wall Street Zen

Crescent Biopharma (NASDAQ:CBIO) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Sunday.

CBIO has been the topic of several other research reports. Wedbush assumed coverage on Crescent Biopharma in a research report on Monday, July 14th. They set an “outperform” rating and a $27.00 price target on the stock. Lifesci Capital raised Crescent Biopharma to a “strong-buy” rating and set a $22.00 price target on the stock in a research report on Wednesday, June 18th. TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a research report on Friday, June 20th. Finally, Stifel Nicolaus assumed coverage on Crescent Biopharma in a research report on Wednesday, June 25th. They set a “buy” rating and a $28.00 price target on the stock. One analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Crescent Biopharma presently has a consensus rating of “Buy” and a consensus price target of $25.67.

Crescent Biopharma Trading Up 2.5%

Shares of Crescent Biopharma stock opened at $13.34 on Friday. Crescent Biopharma has a 52-week low of $11.06 and a 52-week high of $63.00. The company has a market capitalization of $260.80 million, a P/E ratio of -0.29 and a beta of 1.52.

About Crescent Biopharma

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.